Jefferies & Co

Texas Instruments, Inc. (NYSE: TXN) Deutsche Bank writes: 3Q in-line with estimates, weakening macro conditions taken into considerations for 4Q and 2011 estimates. Maintain Hold rating but price target has been reduced to $27. New CY2011 estimates drop to $13.3B/$2.20 from $14.1B/$2.60. Jefferies...

Beckman Coulter, Inc. (NYSE: BEC) announced that Scott Garrett, the current Chairman, President, and CEO, is resigning after eight years, but will continue as a full-time, non-executive employee of the company through January 15, 2011 to assist the board through the transitional period, Jefferies...

Emergency Medical Services Corporation (NYSE: EMS) could prove victorious over a potential contract win in Tacoma, WA, while the Santa Clara contract remains up for grabs. EMS's strong balance sheet well positions AMR Corporation (NYSE: AMR) and at 6.4x EBITDA, EMS remains a Buy rating, according...

Jefferies & Company recently kicked back, put its feet up, and took a look at demand in the beer industry and what it means to stocks in its coverage area. The Jefferies analysts said that, based on their channel checks and comments from the largest beer companies, demand should stabilize...

Analysts at Jefferies & Co reiterate their "buy" rating on Warner Chilcott Ltd (NASDAQ: WCRX). The target price for WCRX is set to $32. According to Jefferies & Co, “The FDA issued its response to WCRX's Citizen's Petition regarding approval of generic formulations of Asacol and Asacol HD....

Analysts at Jefferies & Co reiterate their "hold" rating on Entergy (NYSE: ETR), while reducing their estimates for the company. The target price for ETR has been reduced from $82 to $80. Jefferies & Co says, “We believe Entergy's current share price adequately reflects risk associated with...

Analysts at Jefferies & Co reiterate their "buy" rating on Celgene Corp (NASDAQ: CELG). The target price for CELG is set to $64. Jefferies & Co says, “Celgene's Revlimid became eligible for a generic challenge since December 27, 2009, so today's Paragraph IV filing should come as no...

Analysts at Jefferies & Co maintain their "hold" rating on Kensey Nash (NASDAQ: KNSY), while raising their estimates for the company. The target price for KNSY is set to $21. Jefferies & Co says, “KNSY reported F4Q:10 revenue and adjusted EPS of $21.9M and $0.54 which was slightly ahead of...

Analysts at Jefferies & Co reiterate their "hold" rating on Koppers Holdings (NYSE: KOP), while reducing their estimates for the company. The target price for KOP is set to $26. According to Jefferies & Co, “Seasonal declines in co-products should also translate into narrower spreads...

Jefferies & Co. is out with a research report highlighting the consumer products sector, and companies such as Avon Products (NYSE: AVP) and Tupperware (NYSE: TUP). In the report Jefferies & Co. writes, "“Momentum indicators” for these companies generally remained strong in the 2Q. HLF saw...

Jefferies & Company is out with a research report this morning, where it reiterates its Buy rating on Tupperware (NYSE: TUP); it has a $60.00 price target on the name. The Jefferies analysts cited a recent meeting with management, where the take aways were that the incident in Russia appears...

Jefferies & Company is out with a research report this morning, where it reiterates its Buy rating on Susser Holdings (NASDAQ: SUSS); it has a $14.00 price target on the stock. The Jefferies analysts cited the company’s recent earnings report, which was better than expectations due to better...

Analysts at Jefferies & Co reiterate their "hold" rating on SunPower Corporation (NASDAQ: SPWRA), while raising their estimates for the company. The target price for SPWRA is set to $13. Jefferies & Co says, “SPWR 2Q10 results benefited from one-time gains and unexpected electricity revenue...

Analysts at Jefferies & Co reiterate their "buy" rating on Concur Technologies (NASDAQ: CNQR). The target price for CNQR is set to $54. According to Jefferies & Co, “Industry participants were positive on recent trends in corporate travel (albeit with some renewed caution on Europe). CNQR...

Analysts at Jefferies & Co reiterate their "hold" rating on Myriad Genetics Inc (NASDAQ: MYGN), while revising their estimates for the company. The target price for MYGN is set to $17. According to Jefferies & Co, “MYGN reported a decent F4Q with test volumes slightly up sequentially...